Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients
NCT ID: NCT00038220
Last Updated: 2006-07-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
40 participants
INTERVENTIONAL
2000-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lopinavir/ritonavir
Efavirenz
Lamivudine
Tenofovir DF
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18 to 65 years old.
* Show no signs of recent illness other than HIV infection.
* Agree to use a barrier method of birth control during the study and for 30 days after study.
Exclusion Criteria
* Are pregnant or breast-feeding.
* Are unable to take medications by mouth.
* Have chronic nausea or vomiting.
* Have cancer other than Kaposi's sarcoma or basal cell carcinoma.
* Have active, serious infections (other than HIV) requiring antibiotic injections within 15 days prior to screening.
* Are taking any medications that are not allowed with ABT-378/r and efavirenz.
* Are taking or have taken any other experimental drugs, antiretroviral drugs, or drugs that affect the immune system within 30 days of start of study without consent of the medical monitor.
* Are receiving or have received radiation therapy within 30 days of start of study without consent of the medical monitor.
* Have a history of drug abuse or mental illness that would prevent the patient from following the protocol requirements.
* Have a history of kidney or bone disease.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Abbott
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Scott Brun, M.D.
Role: STUDY_DIRECTOR
Head, Antiviral Global Project Team
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aaron Diamond AIDS Research Center - Rockefeller University
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M00-154
Identifier Type: -
Identifier Source: org_study_id
NCT00006189
Identifier Type: -
Identifier Source: nct_alias